Signal from the log
Aureka Biotechnologies
100 M$ · Series B · Biotech
Société fondée en 2023 qui construit des modèles de fondation biologiques et l'infrastructure expérimentale qui les entoure, pour concevoir des molécules de novo et prédire structure et fonction. Elle a ouvert le code d'un modèle d'anticorps qu'elle annonce supérieur à AlphaFold 3, et a levé près de 200 M$ au total.
Verified
Announced on , logged by the watch of 11 August 2026.
- Operation
- Funding round
- Announced amount
- 100 M$
- Stage
- Series B
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Granite Asia , with HighLight Capital , MPCi , NRL Capital
Provenance
Source endpoints,prnewswire
Logged on 11 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.